This MedLibrary.org supplementary page on Bromopride is provided directly from the open source Wikipedia as a service to our readers. Please see the note below on authorship of this content, as well as the Wikipedia usage guidelines. To search for other content from our encyclopedia supplement, please use the form below:
Related Sponsors
 |
|
|
Bromopride
|
|
| Systematic (IUPAC) name | |
| 4-amino-5-bromo-N-(2-diethylaminoethyl)- 2-methoxybenzamide |
|
| Identifiers | |
| CAS number | |
| ATC code | A03 |
| PubChem | |
| Chemical data | |
| Formula | C14H22BrN3O2 |
| Mol. mass | 344.248 g/mol |
| Pharmacokinetic data | |
| Bioavailability | 50 to 75% (oral) 78% (intramuscular) |
| Protein binding | 40% |
| Metabolism | Hepatic |
| Half life | 4 to 5 hours |
| Excretion | Renal, 10 to 14% unchanged |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | Oral, IM, IV |
Bromopride (INN) is a dopamine antagonist with prokinetic properties widely used as an antiemetic, closely related to metoclopramide. It is not available in the United States.
Bromopride appears to be safe and effective for use in pregnancy.[1]
Contents |
Indications
Bromopride is indicated in the treatment of nausea and vomiting, including postoperative nausea and vomiting (PONV); gastroesophageal reflux disease (GERD/GORD); and as preparation for endoscopy and radiographic studies of the gastrointestinal tract. The manufacturer also claims it is valuable in, among other indications, hiccups and gastrointestinal adverse effects of radiation therapy.
Adverse effects
Bromopride is generally well tolerated; the most common adverse effects of its use are somnolence and fatigue. Bromopride may rarely cause extrapyramidal symptoms and, as metoclopramide, may increase prolactin levels.[2]
Chemistry
Bromopride is a substituted benzamide, closely related to metoclopramide.[3] It is identical to metoclopramide except for the presence of a bromine atom where metoclopramide has a chlorine substituent.
Availability
Bromopride is not available in the United States or the United Kingdom. It is marketed in Brazil by Sanofi-Synthélabo under the trade name Digesan and as a generic drug.
References
- ^ Araújo JR (1981). "Evaluation of bromopride in nausea and vomiting of pregnancy" (in Portuguese). J Bras Ginecol 91 (4): 283–5.
- ^ "Bula do Profissional de Saúde: Bromoprida" (in Portuguese). Bulário Eletrônico da Anvisa. Brazilian National Health Surveillance Agency (April 11, 2006). Retrieved on 2007-07-23.
- ^ Brodie RR, Chasseaud LF, Darragh A, Lambe RF, Rooney L, Taylor T (1986). "Pharmacokinetics and bioavailability of the anti-emetic agent bromopride". Biopharm Drug Dispos 7 (3): 215–22. doi:. PMID 3730521.
|
||||||||||||||||||||||
Wikipedia content modification information:
- This page was last modified on 27 July 2007, at 03:00.
Wikipedia Authorship and Review
Wikipedia content provided here is not reviewed directly by MedLibrary.org. Wikipedia content is authored by an open community of volunteers and is not produced by or in any way affiliated with MedLibrary.org.
Wikipedia Usage Guidelines
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article on "Bromopride".
The URL for this specific entry is:
All Wikipedia text is available under the terms of the GNU Free Documentation License. (See Copyrights for details). Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc.